Jihui Hao
Tianjin Medical University Cancer Institute and Hospital · Tianjin Cancer Hospital Airport Hospital · Tianjin Medical University affiliated Cancer Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jihui Hao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:38 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07791550 · Baduanjin for Quality of Life in Pancreatic Cancer ChemotherapyTianjin Medical University Cancer Institute and Hospital · not yet recruiting · Pancreatic Neoplasms, Pancreatic Cancer, Drug-Related Side Effects and Adverse Reactions (MeSH Term) · principal investigator
- Ph3NCT07436741 · Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerTianjin Medical University Cancer Institute and Hospital · recruiting · Pancreatic Cancer, Adult · principal investigator
- Ph2NCT06413017 · Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment FailureTianjin Medical University Cancer Institute and Hospital · unknown · HCC · study chair
- Ph2/Ph3NCT06409429 · Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic CancerTianjin Medical University Cancer Institute and Hospital · not yet recruiting · Pancreatic Cancer · study chair
- Ph2NCT06405685 · Nimotuzumab Plus AG in Pancreatic Cancer With Liver MetastasisTianjin Medical University Cancer Institute and Hospital · unknown · Pancreatic Cancer · study chair
- Ph2/Ph3NCT06361888 · A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerHutchmed · recruiting · Metastatic Pancreatic Cancer · principal investigator
- Ph1/Ph2NCT06259058 · Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic CancerTianjin Medical University Cancer Institute and Hospital · not yet recruiting · Pancreatic Cancer · principal investigator
- N/ANCT05997147 · A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal AdenocarcinomaTianjin Medical University Cancer Institute and Hospital · unknown · Predictive Cancer Model, Pancreas Cancer · study chair
- Ph2NCT05947825 · Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC PatientsTianjin Medical University Cancer Institute and Hospital · enrolling by invitation · PDAC - Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph2NCT05908747 · Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic CancerTianjin Medical University Cancer Institute and Hospital · completed · Pancreatic Cancer · principal investigator
- Ph1NCT05868876 · A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant TumorsAkeso · completed · Advanced Malignant Tumors · principal investigator
- Ph3NCT05594927 · Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)Beijing Shenogen Biomedical Co., Ltd · unknown · Hepatocellular Carcinoma · principal investigator
- Ph1/Ph2NCT05559541 · Study of AK119 Combined With AK104 in Patients With Advanced Solid TumorsAkeso · terminated · Solid Tumor, Adult · principal investigator
- Ph1NCT05173792 · Study of AK119 in Subjects With Advanced Solid TumorsAkeso · completed · Solid Tumor · principal investigator
- Ph1NCT05149027 · A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid TumorsHarbour BioMed (Guangzhou) Co. Ltd. · unknown · Solid Tumors · principal investigator
- Ph1NCT05125523 · A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid TumorsCSPC ZhongQi Pharmaceutical Technology Co., Ltd. · unknown · Advanced Solid Tumors · principal investigator
- Ph1NCT04482257 · Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.CSPC Ouyi Pharmaceutical Co., Ltd. · unknown · Advanced Pancreatic Cancer · principal investigator
- Ph1NCT03236883 · Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic CancerTianjin Medical University Cancer Institute and Hospital · unknown · Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:38 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study.BMC Cancer · 201712 citationsRCR 0.4
- 8 citationsRCR 2.1
- T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial.Mol Ther · 20266 citationsRCR 3.0
- Safety and efficacy of intraoperative radiation therapy using a low-energy X-ray source for resectable pancreatic cancer: an interim evaluation of an ongoing prospective phase II study.Cancer Biol Med · 20250 citationsRCR 0.0